Retina Consultants of Western New York strives to educate and treat our patients with precision, confidence and dedication. With these three ideals in mind we actively participate in clinical studies that we feel further the care of our patients. The following, lists our active clinical studies, as well as upcoming studies.
1. Uveitis –
The purpose of this study is to evaluate the safety and efficacy of intravitreal injections of DE-109 ophthalmic solution. in Uveitis treatment.
2. Santen: P.I. – Dr.Ram
The purpose of this study is to evaluate the safety and efficacy of intravitreal injections of DE-109 ophthalmic solution in A Phase III, Multinational, Multicenter, Randomized, Double-Masked, Study for the Treatment of Active, Non-Infectious Uveitis
3. Genetech / Roche: P.I. – Dr. Lee
This two year study is a Phase III, double-masked, multicenter, randomized, sham injection-controlled study evaluating the efficacy and safety of lampalizumab administered by intravitreal injections in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
4. Regeneron: P.I. – Dr. Jermak
The primary objective of the one year study is to explore the effect of REGN2176-3 on the Early Treatment Diabetic Retinopathy Scale (ETDRS) best-corrected visual acuity (BCVA) in patients with neovascular age-related macular degeneration (AMD), compared to intravitreal aflibercept injection (IAI) monotherapy.
Soon to be active Studies:
1. Allergan: P.I. – Dr. Ram
A two year multicenter, randomized, double-masked, parallel-group, active-controlled study to assess the safety and efficacy of abicipar pegol compared with ranibizumab in treatment-naïve patients with neovascular Age-related Macular Degeneration
1. Diabetic Macular Edema (DME) –
The purpose of this study is to determine the efficacy of intravitreally (IVT) administered VEGF Trap-Eye on the best corrected visual acuity (BCVA) assessed by the early treatment diabetic retinopathy study (ETDRS) chart in patients with diabetic macular edema (DME) with central involvement.
2. Branch Retinal Vein Occlusion (BRVO) –
This is a phase III, double-masked, randomized, active-controlled, parallel-group, 52-week study to assess the efficacy and safety of VEGF Trap-Eye compared to laser treatment in patients with macular edema secondary to BRVO.
3. Diabetic Retinopathy –
This study is being conducted to determine if intravitreal injections of ranibizumab decrease the proportion of eyes in which vitrectomy is performed compared with saline injections in eyes presenting with vitreous hemorrhage from proliferative diabetic retinopathy.